Selinexor for CLL - mechanism of action and combination with ibrutinib
New targets in relapsed/refractory multiple myeloma patients
The regulation of biosimilars
Shifting the focus in lymphoma treatment
Are combination therapies more effective for the treatment of relapsed refractory CLL?